Related Experiment Video

Updated: May 9, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B

R Cipriano1, B L Bryson1, K L S Miskimen1

  • 1Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.

Oncogene
|August 6, 2013
PubMed

Insights

Researchers identified FAM83B as a novel oncogene that drives cancer by increasing Phospholipase D (PLD) activity and interacting with the epidermal growth factor receptor (EGFR). Targeting this interaction may offer new cancer therapy strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Targeted anticancer therapies are advancing, yet new therapeutic targets are crucial for expanding treatment options.
  • FAM83B has been identified as a potential oncogene involved in human mammary epithelial cell transformation.

Purpose of the Study:

  • To elucidate the mechanism by which FAM83B contributes to cancer development.
  • To investigate the role of FAM83B in regulating Phospholipase D (PLD) activity and its interaction with the epidermal growth factor receptor (EGFR).

Main Methods:

  • Investigated the effect of FAM83B expression on PLD activity in human mammary epithelial cells.
  • Examined the interaction between FAM83B and EGFR using site-directed mutagenesis.
  • Assessed the impact of FAM83B ablation on EGFR phosphorylation, MAPK signaling, and cell proliferation in breast cancer cells.

Main Results:

  • Elevated FAM83B expression increases PLD activity, which is essential for FAM83B-mediated cell transformation.
  • FAM83B interacts with EGFR, and this interaction is critical for engaging PLD activity.
  • Preventing the FAM83B/EGFR interaction suppresses PLD activity, MAPK signaling, and cell proliferation.
  • Ablation of FAM83B inhibits EGFR phosphorylation and reduces breast cancer cell growth.

Conclusions:

  • FAM83B acts as an oncogene by mediating the interaction between EGFR and PLD, thereby activating downstream signaling pathways.
  • Understanding the FAM83B-EGFR-PLD axis provides a basis for developing novel cancer therapies targeting this pathway.
  • FAM83B represents a promising therapeutic target for cancers driven by EGFR signaling.

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line06:24

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line

Published on: April 11, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...